[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cachexia-cancer-sarcopenia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cachexia-cancer-sarcopenia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644523","spatial-multi-omics-and-intelligent-early-warning-of-pancreatic-cancer-cachexia-100644523",false,"NCT07670286","Spatial Multi-omics and Intelligent Early Warning of Pancreatic Cancer Cachexia","Spatial Multi-omics Mechanism Analysis and Multimodal Intelligent Early Warning of Cachexia in Pancreatic Cancer","Inclusion Criteria:\n\n* Patients with pathologically confirmed pancreatic ductal adenocarcinoma.\n* Aged ≥18 years with an expected survival time of ≥1 month (to be assessed for the advanced cohort). Assessment criteria: Comprehensive evaluation based on the patient's radiological tumor burden, vital organ function and physical status. Specific quantitative indicators: Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2, or Karnofsky Performance Status (KPS) score of ≥60. For patients in the advanced cohort, the assessment shall be jointly confirmed by two attending physicians with the professional title of associate chief physician or above in combination with radiological examination results.\n* Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Complicated with other untreated malignant tumors or severe mental disorders.\n* Pregnant women or patients unable to cooperate with follow-up.","ALL","18 Years",{"count":19,"type":20},500,"ESTIMATED","1 Year","OBSERVATIONAL","The goal of this observational study is to explore the spatial multi-omics mechanism of cachexia in pancreatic cancer and construct a high-precision multimodal intelligent early warning model for its early diagnosis in pathologically confirmed pancreatic ductal adenocarcinoma patients aged ≥18 years with an expected survival of ≥1 month.\n\nThe main questions it aims to answer are: 1) Can spatial transcriptomics\u002Fmetabolomics reveal the interaction mechanism between tumor microenvironment and metabolism in pancreatic cancer cachexia? 2)Can a multimodal AI early warning model be built to achieve accurate early identification of pancreatic cancer cachexia? Researchers will compare the surgical cohort and advanced cohort to see the differences in cachexia incidence and progression rules among different subgroups. Participants will complete baseline questionnaires on physical and mental state, nutrition and muscle strength, undergo imaging examinations and provide biological samples (blood, feces, tissue etc.), and receive regular follow-ups for updated questionnaires, imaging rechecks and supplementary biological sample collection until death, loss to follow-up or voluntary withdrawal.",[25,26],"Pancreatic Cancer","Cachexia; Cancer; Sarcopenia",[28,29,25,30],"Spatial Multi-omics","Multimodal intelligent","Cachexia","RECRUITING","2026-06-25",{"date":34,"type":35},"2026-06-26","ACTUAL",{"date":37,"type":35},"2026-04-24",{"date":39,"type":20},"2028-08-31",{"name":41,"class":42},"Peking Union Medical College Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":43},"100632911","study-on-the-pathogenesis-and-reversal-strategies-of-cancer-cachexia-based-on-multi-omics-100632911","NCT07519837","Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics","PRCC-MO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Signed informed consent form and voluntary participation in this study\n* Histologically and\u002For cytologically confirmed diagnosis of cancer\n* Patients with gastrointestinal malignancies, including:\n* Esophageal cancer\n* Hepatocellular carcinoma\n* Gastric cancer\n* Cholangiocarcinoma\n* Patients undergoing histopathological examination of primary lesion biopsy or gastrointestinal endoscopic biopsy\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Presence of contraindications to surgery\n* Cognitive dysfunction, psychiatric disorders, impaired consciousness, or inability\u002Funwillingness to cooperate\n* Presence of two or more concurrent primary tumors",{"count":52,"type":20},1000,"INTERVENTIONAL",[55],"NA","Cancer cachexia is a complex systemic metabolic syndrome with high incidence and mortality rates, significantly impacting the prognosis and survival of cancer patients.Current clinical comprehensive intervention approaches can only provide transient symptom relief and fail to fundamentally block or reverse muscle and fat loss. The core challenge lies in the extreme complexity of this pathological mechanism and the lack of early biomarkers.To overcome the limitations of traditional single-dimensional research approaches, this study proposes a combined analysis method utilizing \"multi-omics\" (imaging omics, pathological omics, metabolomics, and metagenomics) to construct a panoramic systemic model spanning macroscopic clinical manifestations and microscopic molecular processes. The aim is to comprehensively elucidate the pathogenesis and metabolic pathways of cachexia, thereby precisely identifying potential therapeutic targets capable of reversing this pathological process.",[26],[59,60,61],"cancer associated cachexia","Multi-omics Integrated Analysis","Mechanism Exploration and Reversal Strategy Research","2026-04-02",{"date":64,"type":35},"2026-04-09",{"date":66,"type":35},"2026-03-18",{"date":68,"type":20},"2028-03-20",{"name":70,"class":42},"China Medical University, China",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":82,"studyType":22,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":43},"100564559","body-composition-in-older-adults-100564559","NCT06630754","Body Composition in Older Adults","An Exploration of Body Composition in Older Adults Undergoing Systemic Anticancer Treatment.","BODI","Inclusion Criteria:\n\n* Adults eligible and accepting of assessment in the SAOP.\n\n  1. adults aged 70 years and over\n  2. a cancer diagnosis\n  3. just starting SACT\n  4. able to provide at least 2 data sets during the study period (baseline + at least 1 research clinic visit)\n  5. willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* No further exclusions","70 Years",{"count":81,"type":20},30,"1 Day","The primary aim of the study is to explore body composition in older adults (aged 70 years and over) with cancer, undergoing systemic anticancer treatment. Additional aims include to explore the extent of body composition changes and whether changes are tumour specific, the incidence for cancer-related cachexia and sarcopenia and finally, how body composition can inform nutritional management of older adults with cancer.\n\nTo do this, the investigators applied for and were awarded funding from a company called Nutricia to pay for a band 4 (0.6 WTE for 7 months) to take monthly body composition measures on the patients who are eligible, accepting of assessment by the Senior Adult Oncology Programme (SAOP) and consent to these measures. Measurements will include an analysis from the Bioelectrical Impedance Analysis (BIA) machine which will quantify fat, lean muscle, and water content; waist to hip ratio; handgrip strength; calf circumferences. Socio-demographic data will also be collected.\n\nDescriptive data analysis will take place to explore possible trends and associations which may inform future research and drive even further personalised care for this growing and typically underrepresented in research, population.",[85,26,86,87,88],"Sarcopenia in Elderly","Body Composition Changes","Older Adults","Nutrition","NOT_YET_RECRUITING","2024-10-04",{"date":92,"type":35},"2024-10-08",{"date":94,"type":20},"2024-11-01",{"date":96,"type":20},"2025-06-01",{"name":98,"class":42},"Royal Marsden NHS Foundation Trust"]